Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1

Autor: C Cheneau, S Barthier, J Lemonnier, Fabrice Andre, C Dubot, L Teixeira, A Escande, T De La Motte Rouge, T Petit, L Arnould, Laurent Arnould, Suzette Delaloge, Jerome Lemonnier, A Marti, L Stefani, F Berger, C Levy, P Barthelemy, S Nguyen, M Gardner, A Lortholary, François-Clément Bidard, J Plaza, L Joly, Thibault de la Motte Rouge, F Andre, I Bièche, C Alleaume, R Sabatier, B Lucas, Ivan Bieche, O Derbel, L Venat-Bouvet, F Del Piano, Florian Clatot, Anne-Claire Hardy-Bessard, Frédérique Berger, Margaux Marce, Thomas Bachelot, Anne Pradines, Jean-Luc Canon, Sandrine Marques, M Achille, H Ammarguellat, O Arsene, T Bachelot, C Bernard-Marty, F-C Bidard, N Bonichon-Lamichhane, N Bonnin, R Bouaita, A Boudrant, V-A Brunel, C Chakiba, F Clatot, F Dalenc, A De Gramont, L Deiana, C Delbaldo, V Delecroix, H Desclos, V D'Hondt, N Dohollou, J-M Ferrero, C Foa, J-S Frenel, C Garnier Tixidre, D Genet, O Gisserot, M Gozy, C Greilsamer, J Grenier, F Guinet, A-C Hardy-Bessard, J-P Jacquin, E Lachaier, S Ladoire, A-P Laurenty, R Le Scodan, N Leduc, E Legouffe, C Levache, F Lorchel, N Marques, J Medioni, A Melis, D Mille, D Mollon, L Moreau, I Moullet, M-A Mouret-Reynier, A Najem, H Orfeuvre, J-F Paitel, B Pistilli, C Riedl, P Soulie, D Spaeth, F Trouboul, C Valmar, H Vegas, A Zannetti, FC Bidard, S Delaloge, A Pradines, JL Canon, S Marques

Publikováno v: BMJ Open, Vol 12, Iss 3 (2022)

Introduction The combination of a CDK4/6 inhibitor with an aromatase inhibitor (AI) has recently become the gold standard for AI-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2−) advanced breast cancer. Howev

Externí odkaz: https://doaj.org/article/8faf6bbc845f4ceeb90674dd08e198da

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Alpelisib and fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the French early access program

Autor: D. Bello Roufai, A. Gonçalves, T. De La Motte Rouge, S. Akla, C. Blonz, J. Grenier, J. Gligorov, M. Saghatchian, C. Bailleux, H. Simon, I. Desmoulins, Z. Tharin, E. Renaud, M. Bertho, M-A Benderra, S. Delaloge, L. Robert, P. Cottu, J. Y. Pierga, D. Loirat, A. Bertucci, B. Renouf, F. C. Bidard, F. Lerebours

Publikováno v: Oncogene.

SOLAR-1 and BYLieve trials documented the efficacy of the PI3K-inhibitor alpelisib in pre-treated PIK3CA-mutant, hormone receptor-positive, HER2-negative (HR+/HER2-) advanced breast cancer (ABC) patients. We report here real-life datda of patients pr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fdba2c376550828211ea840012464bf3
https://doi.org/10.1038/s41388-022-02585-3

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

13O Impact of surgery and chemotherapy in ovarian sex cord-stromal tumors from the multicentric Salomé study including 469 patients: A TMRG and GINECO group study

Autor: B. Hanvic, F. Lecuru, H. Vanacker, P. Pautier, F. Narducci, F. Cherifi, A. Floquet, M.A. Angeles, D. Berton-Rigaud, C. Pomel, E. Kalbacher, M. Provansal Gross, Y. Fernandez, T. De La Motte Rouge, F. Selle, P. Meeus, C. Genestie, J. Salleron, I.L. Ray-Coquard

Publikováno v: ESMO Open. 8:101034

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::57ecc80db63b4d8b128c56afd327655a
https://doi.org/10.1016/j.esmoop.2023.101034